ATS View
한국어

DongKoo Bio & Pharma KRX:006620KOSDAQ

동구바이오제약 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h11
Articles, 7 days11
DART filings, 7 days1
Articles tracked11since Sep 11

In Q2 2026, DongKoo Bio & Pharma reported revenue of ₩59.5bn, down 1.1% year on year, and an operating loss of ₩6.5bn. DongKoo Bio & Pharma (동구바이오제약) appeared in 11 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Sep 15 with 11 articles.

DongKoo Bio & Pharma quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩59.5bn-1.1%−₩6.5bn−₩6.1bn
Q1 2026₩58.1bn-1.0%₩1.8bn−₩578m
Q4 2025 derived₩61.9bn+7.5%₩2.8bn₩41.2bn
Q3 2025₩62.0bn-6.3%₩2.2bn−₩1.6bn
Q2 2025₩60.1bn-1.9%₩1.9bn₩11.3bn
Q1 2025₩58.7bn-8.6%₩2.3bn−₩721m
Q4 2024 derived₩57.6bn-7.2%−₩482m−₩8.2bn
Q3 2024₩66.2bn+25.2%₩7.0bn₩3.6bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.

DongKoo Bio & Pharma top stories 2 weeks, by number of outlets

  1. 1
    동구바이오제약, GMP 취소처분 효력 일시 정지…“생산·공급 정상”
    6 outlets · 6 articlesFirst report Sep 15 08:29 한국경제
  2. 2
    동구바이오제약, GMP 취소처분 효력 정지…“사업운영 차질 없어”
    3 outlets · 3 articlesFirst report Sep 15 08:13 더바이오
  3. 3
    동구바이오제약, GMP 취소처분 소송 1심 패소에도 생산·공급 지속
    1 outlets · 1 articlesFirst report Sep 15 10:51 코메디닷컴
  4. 4
    동구바이오제약, GMP 취소 효력 정지…항소심 대응
    1 outlets · 1 articlesFirst report Sep 15 08:51 한스경제

Latest DongKoo Bio & Pharma news Korean headlines